Editas Medicine, Inc. EDIT announced that the FDA has granted Orphan Drug designation to its investigational gene-editing medicine, EDIT-301, for the treatment of beta thalassemia, a devastating ...
CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results